Table 2 Co-medication of the subgroups of patients treated with either iloprost (n = 16) or bosentan (n = 11)
Co-medication | Iloprost | Bosentan |
|---|---|---|
Calcium channel blockers | 10 (62.5%) | 7 (63.7%) |
Acetyl salicylic acid | 7 (43.8%) | 6 (54.5%) |
Nitrates | 3 (18.8%) | 2 (18.2%) |
β-blockers | 1 (6.3%) | 3 (27.3%) |
Diuretics | 2 (12.5%) | 3 (27.3%) |
ACE-inhibitors | 2 (12.5%) | 2 (18.2%) |
Statins | 2 (12.5%) | 1 (9.1%) |
Systemic steroids | 5 (31.3%) | 4 (36.4%) |
Methotrexate | 4 (25%) | 1 (9.1%) |
Azathioprine | 0 (0%) | 1 (9.1%) |
Analgesics | 16 (100%) | 10 (90.9%) |
Antidepressants | 4 (25%) | 3 (27.3%) |
Proton pump inhibitors | 15 (93.8%) | 10 (90.9%) |
Thyroxine | 3 (18.8%) | 2 (18.2%) |
Warfarin | 0 (0%) | 1 (9.1%) |